(Q35925631)

11 August 2017

1 reference

title

The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

11 August 2017

0 references

author name string

Gilbert Bensimon

series ordinal

1

1 reference

PubMed ID

15500412

11 August 2017

Adam Doble

series ordinal

2

1 reference

PubMed ID

15500412

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Drug Safety

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

6

1 reference

11 August 2017

525-534

1 reference

Unraveling the mechanisms involved in motor neuron degeneration in ALS

11 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Progress in the pathogenesis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Acute hepatitis after riluzole administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Long-term safety of riluzole in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Renal tubular impairment during riluzole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Reversible granulocytopenia in association with riluzole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Riluzole-induced acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Riluzole-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

Riluzole-induced methemoglobinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.525

21 January 2018

Identifiers

DOI

10.1517/14740338.3.6.525

1 reference

11 August 2017

1 reference

PubMed ID

15500412